Lixte Biotechnology (LIXT)
Develops LB-100 and proton therapy technology for cancer treatment.
$7.21
At close−0.46 (−6.00%)
In millions of USD, except per-share figures
| In millions | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | |
| Research & development | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | |
| General & administrative | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 |
| Operating income | −1 | −1 | −1 | −1 | −1 | −1 | −1 | −1 | −2 | −2 | −2 | −2 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | −1 | 0 | 0 | |
| Interest income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other non-operating income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Income before tax | −1 | −1 | −1 | −1 | −1 | −1 | −1 | −1 | −2 | −3 | −2 | −2 |
| Net income from continuing operations | −1 | −1 | −1 | −1 | −1 | −1 | −1 | −1 | −2 | −3 | −2 | −2 |
| Net income | −1 | −1 | −1 | −1 | −1 | −1 | −1 | −1 | −2 | −3 | −2 | −2 |
| EPS, basic | −$0.49 | −$0.46 | −$0.43 | −$0.45 | −$0.44 | −$0.27 | −$0.29 | −$0.29 | −$0.33 | −$0.33 | −$0.18 | −$0.16 |
| EPS, diluted | −$0.49 | −$0.46 | −$0.43 | −$0.45 | −$0.44 | −$0.27 | −$0.29 | −$0.29 | −$0.33 | −$0.33 | −$0.18 | −$0.16 |
| Weighted average shares, basic | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 6 | 48 | 11 | 13 |
| Weighted average shares, diluted | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 6 | 48 | 11 | 13 |
| EBITDA | −1 | 0 | −1 | −1 | −1 | 0 | 0 | −1 | −2 | −3 | −2 | −2 |
| Depreciation & amortization | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| EBIT | −1 | −1 | −1 | −1 | −1 | −1 | −1 | −1 | −2 | −3 | −2 | 0 |